Metastatic RCC is usually resistant to conventional chemotherapy whereas only immunotherapy with interferon alpha (IF-α) or interleukin-2 (IL-2) has been demonstrated to provide significant results in terms of disease-free survival.4–6. The gene discussed is IL2; the disease is renal cell carcinoma.